8-K: Autolus Therapeutics Reports Positive Momentum with AUCATZYL Launch and Outlines Expansion Plans

Autolus Therapeutics announces its Q4 and full year 2024 financial results, highlighting the successful U.S. commercial launch of AUCATZYL and plans for future growth in autoimmune diseases.

Summary

• Autolus Therapeutics reported its financial results for the year ended December 31, 2024.
• The company is progressing with the U.S. commercial launch of AUCATZYL, with 33 authorized treatment centers as of March 19, 2025.
• Marketing authorizations for obe-cel in the UK and EU are expected in the second half of 2025.
• The company has dosed six patients in a Phase 1 dose confirmation trial for Systemic Lupus Erythematosus (SLE).
• An R&D investor event is scheduled for April 23rd to provide updates on clinical development programs, including expansion into autoimmune diseases.
• Cash, cash equivalents, and marketable securities totaled $588.0 million at the end of 2024, compared to $239.6 million at the end of 2023.
• The loss from operations for the year ended December 31, 2024, was $241.4 million, compared to $179.7 million for the year ended December 31, 2023.
• Net loss for the year ended December 31, 2024, was $220.7 million, compared to $208.4 million for the same period in 2023.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful commercial launch of AUCATZYL, strong cash position, and plans for future growth. However, the increasing losses temper the overall sentiment.

Positives

• AUCATZYL's U.S. commercial launch is progressing on track, exceeding the initial target for treatment centers.
• Patient access to AUCATZYL is progressing well, with coverage secured for greater than 85% of total U.S. medical lives.
• Obe-cel is under regulatory review in both the EU and the U.K., and the Company expects to receive notification of approval status from the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA) in H2 2025.
• The company's cash position is strong, with $588.0 million in cash, cash equivalents, and marketable securities at the end of 2024.
• The FDA approval for AUCATZYL triggered a $30 million milestone payment to Autolus from Blackstone.

Negatives

• The loss from operations for the year ended December 31, 2024, was $241.4 million, as compared to $179.7 million for the year ended December 31, 2023.
• Net loss was $220.7 million for the year ended December 31, 2024, compared to $208.4 million for the same period in 2023.

Risks

• The company's ability to generate revenues from AUCATZYL is dependent upon maintaining significant market acceptance among physicians, patients and healthcare payors.
• The company's ability to obtain and maintain regulatory approval for obe-cel for adult r/r B-ALL in additional territories and the timing thereof.
• The company's expectations regarding the commercialization and marketing of AUCATZYL for adult r/r B-ALL, including expanding into additional territories and the related timing of reaching patients in such territories.
• The development of additional product candidates, including statements regarding the initiation, timing, progress and the results of clinical studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs.
• The timing or likelihood of regulatory filings and approvals for product candidates, along with regulatory developments in the US, EU, the UK and other foreign countries.
• Size and growth potential of the markets for AUCATZYL and product candidates, if approved.
• Estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

Future Outlook

Autolus estimates that, with its current cash and cash equivalents and marketable securities, it is well capitalized to drive the launch and commercialization of obe-cel in r/r adult B-ALL in the U.S., UK and EU, as well as to advance its pipeline development plans, which includes providing runway to data in the first pivotal clinical trial of obe-cel in autoimmune disease.

Management Comments

• Reflecting on 2024, it was a year of strong execution leading to significant achievements for Autolus, including our strategic deal with BioNTech and corresponding financing to bolster our balance sheet, commencing GMP operations at our in-house CAR T manufacturing facility, and finishing the year with our first FDA approval and the commercial launch of AUCATZYL, said Dr. Christian Itin, Chief Executive Officer of Autolus.
• As a result, we were well positioned to attain our most important goal of bringing this transformative therapy to patients in need.
• Physician enthusiasm for AUCATZYL is high, demonstrated by the 33 treatment centers we now have fully authorized as of March 19, 2025.
• Were encouraged by our launch progress to date.
• As we begin 2025, we have two key objectives: execute on the commercial launch of AUCATZYL in adult ALL both in the U.S. and entering new markets; and establish the next wave of investments to expand the obe-cel opportunity, advance our clinical pipeline and drive future growth.
• We look forward to discussing our plans to continue to expand our clinical pipeline and strategy at our R&D event in April.

Industry Context

Autolus Therapeutics is operating in the competitive CAR T-cell therapy space, focusing on hematological malignancies and expanding into autoimmune diseases, which aligns with the broader industry trend of exploring CAR T-cell therapy for indications beyond cancer.

Comparison to Industry Standards

• The 33 authorized treatment centers for AUCATZYL as of March 19, 2025, indicate a strong initial launch, comparable to other CAR T therapies like Novartis' Kymriah and Gilead's Yescarta.
• The company's focus on expanding into autoimmune diseases with obe-cel positions it alongside companies like Kyverna Therapeutics, which are also exploring CAR T-cell therapy for autoimmune conditions.
• The FELIX trial data published in the New England Journal of Medicine demonstrates high rates of durable responses with low incidence of greater than Grade 3 immune-related toxicity, which is competitive with other CAR T therapies in the market.
• Autolus' proprietary CAR T manufacturing facility, The Nucleus, designed for 2,000+ batches per year, positions it well to meet the growing demand for CAR T therapies.

Stakeholder Impact

• Shareholders: The successful launch of AUCATZYL and strong cash position are positive for shareholders.
• Employees: The company's growth plans and expansion into new markets are positive for employees.
• Patients: The availability of AUCATZYL and potential approval of obe-cel provide new treatment options for patients.
• Healthcare Payors: The company is working to secure coverage for AUCATZYL, which will impact healthcare payors.

Next Steps

• The company will present clinical development program updates, including plans for expansion in autoimmune diseases, at an R&D investor event on April 23rd.
• The company expects to receive notification of approval status from the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA) in H2 2025.
• Autolus will present initial data from the SLE Phase 1 trial and development plans at its R&D event on April 23, 2025, and is targeting H2 2025 for the presentation of full data with longer term patient follow-up.

Key Dates

Keywords

AUCATZYL, obe-cel, Autolus Therapeutics, CAR T therapy, B-cell ALL, autoimmune diseases, commercial launch, regulatory approval, clinical trials, financial results